文献速递肝病消化道肿瘤与早癌

Doylestown Plus与GALAD在肝硬化患者中检测肝细胞癌的敏感性

Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-04-20

本研究在肝硬化患者巢式病例对照研究中比较包括AFP、GALAD和Doylestown Plus在内的多种生物标志物对肝细胞癌(HCC)的检测性能。背景指出半年一次腹部超声联合或不联合AFP的监测策略在早期阶段遗漏超过三分之一的HCC,而GALAD和Doylestown Plus在II期病例对照研究中显示有前景的准确性,但病例对照研究可能高估性能,需III期队列研究验证。

要点

  • 半年一次超声联合或不联合AFP监测在早期阶段遗漏超过三分之一的HCC。
  • GALAD和Doylestown Plus在II期病例对照研究中显示有前景的准确性。
  • 病例对照研究可能高估生物标志物性能,需III期研究验证。

核心结论

  • 研究旨在肝硬化患者巢式病例对照研究中比较AFP、GALAD和Doylestown Plus等多种生物标志物对HCC的检测性能。

研究设计与样本

  • 巢式病例对照研究,对象为肝硬化患者。

主要发现

  • 半年一次腹部超声联合或不联合AFP监测在早期阶段遗漏超过三分之一的HCC。
  • GALAD和Doylestown Plus在II期病例对照研究中显示有前景的准确性。

局限性

  • 病例对照研究可能高估生物标志物性能,需III期队列和巢式病例对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) surveillance is associated with early tumor detection and improved survival in patients with cirrhosis.1 Surveillance is performed using semiannual abdominal ultrasound with or without α-fetoprotein (AFP); however, this strategy misses more than one-third of HCC at an early stage.2 These data highlight a need for novel surveillance strategies with higher accuracy for early HCC detection. GALAD and Doylestown Plus are novel biomarker panels that combine multiple biomarkers with patient demographic and clinical characteristics; both demonstrated promising accuracy in phase II case-control studies;3,4 however, case-control studies can overestimate biomarker performance, highlighting a need for phase III cohort and nested case-control studies.5 Our study aimed to compare multiple biomarkers (including AFP, GALAD, and Doylestown Plus) in a nested case-control study of patients with cirrhosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Singal AG, Tayob N, Mehta A, et al. Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2021. PMID: 33864933. doi:10.1016/j.cgh.2021.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。